lan;02dec00 SEMINAR 1914 THE LANCET ° Vol 356 ° December 2, 2000 Method Percentage of unintended pregnancies within first year of use Typical use Perfect use Chance 85% 85% Oral contraceptives Combined 5% 0· 1% Progestagen- only 0· 5% Depot progestagen 0· 3% 0· 3% Subdermal implants Norplant 0· 05% 0· 05% Implanon 0 0 Intrauterine devices Copper...
author: bos
lan;02dec00 page 3
author: bos
No Slide Title – – Partnerships to provide access to primary care Add-on products reinforce sales efficiency Pharma Day - 2002 Organon Customer focused and efficient marketing • Simplify existing operations – – – from six to four regions – – to faster identify and prioritize opportunities • • Restructure organization – – build functional...
author: Wim Mol
01-287 PhRMA NewMed WomenforPDF Triangle Park, NC human papilloma- Merck prevention of human Phase II virus (HPV) Whitehouse Station, NJ papillomavirus (800) 672- 6372 vaccine (see also cancer) Implanon ª Organon contraception Phase III etonogestrel West Orange, NJ (800) 241- 8812 INS- 1 INSMED infertility, polycystic ovary Phase II Richmond, VA syndrome (804) 565- 3022 Taisho (see also diabetes)...
author: RL
01-287 PhRMA NewMed WomenforPDF page 21
author: RL
Slide 1 Akzo Nobel User Slide 1 Akzo Nobel Fritz Froehlich – CFO & Deputy Chairman Lehman Brothers Global Chemical Industry Leaders Conference Lisbon, April 1, 2004 · Strategy · Our performance Strong position 3 groups: Pharma, Coatings & Chemicals Outlook 2004 Agenda Leading positions - globally active 2003 in EUR bln Sales: 13.1 Strategy Coatings 5.2 Pharma 3.6 Chemicals 4.4...
author: Akzo Nobel
Presentation T. Wilderbeek Cyclessa) • NuvaRing to be the key growth driver (estimate 2003: EUR 40-50 million) Implanon filing in USA in Q4 2003 “Male pill” in phase II New pill Org 33628 in phase II Fall Analyst Meeting NuvaRing Monthly Sales Volume units Fall Analyst Meeting Menopause Livial Sales level EUR 330 million, of which core product Livial about EUR 200 million, no position in...
author: Joop van Orsouw
Drug Information Journal - - Meetings/Events - Publications - Network Of Members - Interactive Access - Links - - Mission & Vision - Continuing Education Credits - Academic Affiliations - Clinical Investigator Certification - eLearning Courses - Instructor-Led Courses - Job Bank - - Contribute Expertise - Special Interest Area Communities - Association Governance - Submit An Abstract - - Exhibiting -...
lan;02dec00 page 6
author: bos
lan;02dec00 page 2
author: bos
Pharmaceutical Research and Manufacturers of America - Contraception Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes CTR 99 none / CTR 99 Contraception Organon West Orange, NJ application submitted - EVRA EVRA / none Contraception Johnson &Johnson;...
Pharmaceutical Research and Manufacturers of America - Organon Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes CTR 99 none / CTR 99 Contraception Organon West Orange, NJ application submitted - gepirone none / gepirone Depression Organon West Orange, NJ...
http://www.akzonobel.com/misc/downloadabledoc.asp?tp=9&id=npUkO3MkywI%3D&number=1&l=English N E WS & V I E WS ° S E P T E M B E R 2 0 0 3 6 Sales of Organon's NuvaRing contraceptive may have been slow to pick up, but the product is now well on course to hit all its targets
http://www.akzonobel.com/misc/downloadabledoc.asp?tp=9&id=npUkO3MkywI%3D&number=1&l=English page 2
No Slide Title and PVC industry Q1- 2002 results +4% +4% -1% +3% EUR mln/ Q1-02/01 Agenda · Q1 - 2002 results · Pharma update Outlook Contraceptives - continued innovation Sales - Q1 2% 128 Pharma update EUR mln 130 · · · Americas - Upcoming Generic versions · Nuvaring - prelaunch US - full launch US mid 2002 - Europe Q4-02 · Implanon - strong growth - US...
author: Hans Zwerus
No Slide Title Nederlands 7 ACDPS7 No Slide Title Monique Smits _ _AdHocReviewCycleID _EmailSubject standaard presentatie _AuthorEmail Jacqueline.Schrijver@AkzoNobel.com _AuthorEmailDisplayName Schrijver, H.J.LImplanon ...
author: Monique Smits
No Slide Title Livial® + 12 Top 4 key products sales 2002 70% Pharma - protect margins New product flow sales 2003 >2006 Arixtra penetration/ new launches Org 5222 Xyvion Variza Implanon US Andriol Europe Puregon US-Pen/Japan Nuvaring ww S-O34006 Pharma - protect margins Hormones - attractive niches · Contraceptives focus on new delivery mechanisms push growth Implanon push...
author: Hans Zwerus
http://www.akzonobel.com/misc/downloadabledoc.asp?tp=1&id=04rBsv%2B2kN0%3D&number=1&l=English SECURITIES AND EXCHANGE COMMISSION Washington, DImplanon ® Contraceptive implant Market Europe III 2002/ 3 (USA) Nuvaring® Contraceptive ring Filed 2002 Org 30659 OC/...
http://www.akzonobel.com/misc/downloadabledoc.asp?tp=1&id=04rBsv%2B2kN0%3D&number=1&l=English page 30
http://www.akzonobel.com/misc/downloadabledoc.asp?tp=1&id=04rBsv%2B2kN0%3D&number=1&l=English page 21
Deel 2 page 22
author: Dorine van Amerongen
http://www.akzonobel.com/misc/downloadabledoc.asp?tp=1&id=NtyYNWtDCdE%3D&number=1&l=English REPORT for the 1st quarter of 2002 Key figures Millions of euros (EUR) 1 st quarter 2002 2001 !% Net income 234 215 9 TH per share, in EUR 0.82 0.75 Sales Pharma 1,009 960 5/ 13 1 Coatings 1,337 1,362 (2)/ 2 1 Chemicals 1,176 1,182 (1) Total 3,488 3,470 1/ 4 1 Operating income (EBIT) Pharma 210 191 10/ 10 1 Coatings 87 88 (1)/ 2 1 Chemicals 102 99 3 Total 385 371 4/ 4 1 Return on...
http://www.akzonobel.com/misc/downloadabledoc.asp?tp=1&id=NtyYNWtDCdE%3D&number=1&l=English page 4
NED_plat_2001 page 27
author: Paul
Annual_report_alg page 34
author: Aart
